← Back to Search

Cardiac Medication

Ivabradine for Heart Failure (PROBE-IT Trial)

Phase 4
Waitlist Available
Led By Michael R Bristow, MD PhD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

PROBE-IT Trial Summary

This trialinvestigates if ivabradine, a heart-rate reducing drug, can improve ventricular function in HFrEF patients unresponsive to beta-blocker therapy. It aims to reduce mortality and hospitalization rates in these patients.

Eligible Conditions
  • Systolic Heart Failure
  • Dilated Cardiomyopathy
  • Ventricular Remodeling
  • Electrical Remodeling

PROBE-IT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Left ventricular reverse remodeling according to heart rate response
Secondary outcome measures
Comparison of gene expression abundances by heart rate response
Left ventricular reverse remodeling by treatment group (ivabradine vs. placebo)

PROBE-IT Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: IvabradineActive Control1 Intervention
Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
Group II: PlaceboPlacebo Group1 Intervention
Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,732 Previous Clinical Trials
2,143,555 Total Patients Enrolled
26 Trials studying Heart Failure
7,258 Patients Enrolled for Heart Failure
American Heart AssociationOTHER
324 Previous Clinical Trials
4,933,750 Total Patients Enrolled
32 Trials studying Heart Failure
137,779 Patients Enrolled for Heart Failure
Ohio State UniversityOTHER
828 Previous Clinical Trials
505,723 Total Patients Enrolled
18 Trials studying Heart Failure
52,889 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is enrollment available for this medical experiment?

"Unfortunately, this trial is not accepting new patients at the time. It was first posted on November 1st 2016 and last updated on October 31st 2022. If you are searching for other studies related to ventricular remodeling, there are presently 215 clinical trials enrolling participants; conversely, 8 research studies related to Ivabradine require volunteers."

Answered by AI

What conditions is Ivabradine most frequently prescribed for?

"Ivabradine is frequently used to provide relief from congestive heart failure, but can also be taken to manage symptoms of coronary artery disease (CAD), left ventricular dysfunction, and chronic stable heart failure."

Answered by AI

Are there still open slots for people to join this research?

"Clinicaltrials.gov lists this medical trial as inactive; its initial posting was on November 1st 2016, and it last received an update in October 2022. However, there are currently 223 other trials that need patients to partake in them."

Answered by AI

What other research has been done recently to explore the effects of Ivabradine?

"First investigated by the Chair of Cardiology in 2010, Ivabradine has since been studied 18350 times. Currently 8 active trials are ongoing with several based out of Columbus, Ohio."

Answered by AI

Has Ivabradine received its regulatory go-ahead from the FDA?

"Ivabradine's safety is highly regarded and scored a 3; this drug has been approved, which justifies its inclusion in Phase 4 trials."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Pulse Reduction On Beta-blocker and Ivabradine Therapy
2016. "Pulse Reduction On Beta-blocker and Ivabradine Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02973594.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top